FindTrial
Sign In

A clinical study with different doses of the drug tranexemic acid to reduce blood loss in major surgeries

Evaluation of efficacy of different doses and timing of administration of tranexamic acid for reduction of blood loss in major orthopedic surgeries.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011156
Enrollment
200
Registered
2018-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M849- Disorder of continuity of bone, unspecified Health Condition 2: null- patients undergoing major orthopaedic surgeries

Interventions

Intervention1: intravenous drug administration: tranexemic acid is given in different doses and blood loss measured. Control Intervention1: Tranexemic acid: Tranexemic acid is given in different doses

Sponsors

SRM medical college hospital and research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status 1 and 2 patients undergoing major orthopaedic surgeries

Exclusion criteria

Exclusion criteria: 1. revision surgeries 2. allergy to drugs - tranexemic acid, heparin 3. anaemia 4. altered coagulation profile 5. pregnancy 6. previous history of DVT or pulmonary embolism

Design outcomes

Primary

MeasureTime frame
Intraoperative blood loss estimationTimepoint: From the surgical incision to the skin closure—

Secondary

MeasureTime frame
adverse effects of tranexemic acidTimepoint: screening for deep vein thrombosis in the first 3 days of postoperative period;Postoperative blood loss estimationTimepoint: From the end of surgery to first 24 hours—

Countries

India

Contacts

Public ContactSaravanan

SRM Medical college hospital and research centre

drcrsaravanan@gmail.com9884001153

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026